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Vascular aging is the term that describes the structural and functional disturbances of
the vasculature with advancing aging. The molecular mechanisms of aging-associated
endothelial dysfunction are complex, but reduced nitric oxide (NO) bioavailability and altered
vascular expression and activity of NO synthase (NOS) enzymes have been implicated
as major players. Impaired vascular relaxation in aging has been attributed to reduced
endothelial NOS (eNOS)-derived NO, while increased inducible NOS (iNOS) expression
seems to account for nitrosative stress and disrupted vascular homeostasis. Although
eNOS is considered the main source of NO in the vascular endothelium, neuronal NOS
(nNOS) also contributes to endothelial cells-derived NO, a mechanism that is reduced in
aging. Pharmacological modulation of NO generation and expression/activity of NOS iso-
forms may represent a therapeutic alternative to prevent the progression of cardiovascular
diseases. Accordingly, this review will focus on drugs that modulate NO bioavailability,
such as nitrite anions and NO-releasing non-steroidal anti-inflammatory drugs, hormones
(dehydroepiandrosterone and estrogen), statins, resveratrol, and folic acid, since they may
be useful to treat/to prevent aging-associated vascular dysfunction. The impact of these
therapies on life quality in elderly and longevity will be discussed.
Keywords: aging, endothelial dysfunction, nitric oxide, nitric oxide synthases, uncoupled eNOS, statin, resveratrol,
folic acid
INTRODUCTION
Many disorders emerge with advancing aging, and cardiovascular
diseases (CVD) are a major cause of morbidity and mortality in the
elderly1 (Lakatta and Levy, 2003). The term vascular aging encom-
passes all the structural and functional alterations in the blood
vessels with progressive aging (Herrera et al., 2010). Both smooth
muscle cells and intima layers are affected. These vascular changes
lead to endothelial dysfunction, arterial stiffness in consequence
of intense remodeling and calcification, impaired angiogenesis,
greater susceptibility to vascular injury and atherosclerotic lesions
(Lakatta and Levy, 2003; Herrera et al., 2010).
The mechanisms underlying vascular aging are complex and
involve multiple pathways and factors, and a comprehensive
description of all mechanisms is beyond the scope of this review.
Excellent and very recent reviews on the topic are available
1According to the Department of Health Statistics and Health
Information Systems, World Health Organization (WHO),
(http://www.who.int/healthinfo/survey/ageingdefnolder/en/index.html), “Most
developed world countries have accepted the chronological age of 65 years as a
definition of “elderly” or older person,” although this concept does not adapt well
to every country or population. Chronological or “official” definitions of aging
can differ widely from traditional or community definitions of when a person
is older. In many parts of the developing world, chronological time has little or
no importance in the meaning of old age, which is seen to begin at the point
when active contribution is no longer possible. Since in this review the aging
process is being looked from a biological perspective, which has its own dynamic,
largely beyond human control, the chronological aging definition may seem more
appropriate.
(Herrera et al., 2010; Seals et al., 2011; Toda, 2011). In this
complex scenario, vascular function depends on the balanced
production/bioavailability of nitric oxide (NO), which is main-
tained by the normal activity of endothelial nitric oxide synthase
(eNOS). On the other hand, excessive amount of NO produced
by inducible nitric oxide synthase (iNOS) up-regulation con-
tributes to vascular dysfunction. Evidence obtained from exper-
imental models indicates that decreased NO bioavailability as
well as increased reactive nitrogen species (RNS) production con-
tributes to aging-associated vascular dysfunction. These effects
have been attributed to abnormal expression and activity of vas-
cular NO synthase (NOS) isoforms. Accordingly, in this review,
a very brief overview on NO signaling in cardiovascular aging is
provided. The role of each NOS isoform on aging-associated vas-
cular dysfunction is then discussed. The use of drugs that affect
NO generation or modulate NOS expression/activity, includ-
ing nitrite anions, NO-releasing non-steroidal anti-inflammatory
drugs, statins, hormones (estrogen and dehydroepiandrosterone),
resveratrol, and folic acid to prevent vascular dysfunction in elderly
is also addressed.
BRIEF BIOCHEMISTRY OF NO SIGNALING
NO is a highly reactive signaling molecule, produced from the oxi-
dation of the essential amino acid l-arginine by the NOS family
(Figure 1). The eNOS and neuronal nitric oxide synthase (nNOS)
isoforms are constitutively expressed in many tissues, including
vessels and neurons (Melikian et al., 2009; Villanueva and Giulivi,
2010). Conversely, iNOS is expressed by vascular cells in response
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FIGURE 1 | Role of nitric oxide synthase (NOS) enzymes in endothelial
function and aging-associated endothelial dysfunction. Endothelial
(e)-NOS isoform converts l-arginine to nitric oxide (NO). eNOS activity is
determined by intracellular calcium concentration [i(Ca2+)] and/or its
phosphorylation (P) state at different sites (e.g., eNOS is positively and
negatively modulated by phosphorylation of serine 1177 (S1177) and threonine
494 (T494), respectively). In addition, eNOS activity is inhibited by its
interaction with caveolin-1 and by O-GlcNAc modification, while eNOS
association with heat shock protein 90 (hsp90) favors its activation. In
endothelial aging, NO synthesis is compromised because eNOS activity is
decreased due to increased expression and interaction with caveolin, reduced
expression and association with hsp90, reduced phosphorylation of S1177 and
increased phosphorylation of T494. In addition, reduced availability of l-arginine
and tetrahydrobiopterin (BH4) induces eNOS uncoupling or changes the
enzyme to a state that favors superoxide anion (•O−2 ) generation. In aged
endothelial cells, up-regulated iNOS, which may be associated with
NF-κB-induced vascular inflammation, produces high levels of NO. NO reacts
with cysteine residues of proteins (arginase in this example), forming
S-nitrosothiol (-SNO)–arginase, which increases arginase activity and
l-arginine consumption. NO directly reacts with •O−2 produced by uncoupled
eNOS, and other vascular sources, generating the harmful reactive nitrogen
specie peroxynitrite (ONOO−), which contributes to vascular dysfunction. The
aging–associated NOS alterations are depicted in red. ACh, acetylcholine; Bk,
bradykinin; PI3K, phosphoinositide-3-kinase.
to chemokines and invading microorganisms (Hecker et al., 1999).
eNOS and nNOS are calcium (Ca2+)-dependent, while iNOS is
Ca2+-independent. Activation of specific receptors on endothelial
cells (e.g., by bradykinin) increases the intracellular levels of Ca2+,
which in turn, promotes eNOS activation and NO generation in
the vascular system (Figure 1). NO production is also increased as
a consequence of mechanical distension (shear stress) caused by
blood flow on the vascular wall. NO generated by nNOS and iNOS
is classically described as a neurotransmitter and a reactive mol-
ecule involved in bacterial killing, respectively. However, recent
advances highlight the role of nNOS and iNOS in cardiovascular
(dys)function (Melikian et al., 2009; Tsutsui et al., 2009) as well as
in aging, as discussed later.
Nitrite and nitrate anions are known as end products of NO oxi-
dation and reflect endogenous NOS activity (Dejam et al., 2004;
Moncada and Higgs, 2006). However, nitrite can be reduced to
NO by either hypoxia, tissue acidosis conditions, or by a num-
ber of enzymes. This makes nitrite an important complementary
reservoir of NO in physiological conditions (Dejam et al., 2004).
NOS-produced NO reacts rapidly with amino acids residues,
ions, and superoxide anion (•O−2 ), a reactive oxygen species (ROS;
Moncada and Higgs, 2006). The latter reaction is particularly
important since, as a •O−2 scavenger, NO becomes an antioxi-
dant molecule at the same time that its bioavailability is reduced
in the presence of high •O−2 levels. Under conditions of l-arginine
or tetrahydrobiopterin (BH4) deficiency, NOS becomes a radical
generating enzyme, a phenomenon referred as NOS uncoupling.
EVIDENCE FOR A ROLE OF NO IN THE REGULATION OF
LONGEVITY
NO seems to be a key molecule to longevity and cardiovas-
cular health. This concept was partially derived from stud-
ies addressing the cardiovascular function in mice that do not
express at least one, a combination of two, or all NOS isozymes
genes (nNOS−/−; iNOS−/−; eNOS−/−; n/iNOSs−/−; n/eNOSs−/−;
i/eNOSs−/−; n/i/eNOSs−/−; Tsutsui et al., 2009). Accordingly, the
survival rate of 10 month-old triple NOS knockout mice is reduced
by ∼80%, mainly as a consequence of spontaneous myocardial
infarction, coronary arteriosclerosis and mast cell infiltration in
the coronary artery adventitia (Tsutsui et al., 2009). The role of
each NOS is well established in some CVD. For instance, studies in
mice models of atherogenesis demonstrated that eNOS and nNOS
play protective roles, whereas iNOS is pro-atherosclerotic (Tsut-
sui et al., 2009). On the other hand, in particular conditions such
as myocardial ischemia, iNOS up-regulation represents a com-
pensatory molecular mechanism that protects myocardial cells
from damage (Bolli, 2001). However, few studies have addressed
whether chronic ablation of a specific NOS isoform affects lifespan.
A role for eNOS in lifespan and spatial memory was suggested by a
report showing that the survival rate of eNOS knockout mice was
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reduced by 50%. Those mice also exhibit decreased exploratory
behavior at 18–22 weeks of age when compared to age-matched
controls (Dere et al., 2002). In addition, it has been reported
that caloric restriction extends lifespan. However, this effect was
strongly attenuated in eNOS knockout mice (Nisoli et al., 2005).
This implicates eNOS-derived NO as one of the mechanisms by
which caloric restriction extends lifespan.
In humans, an iNOS polymorphism is significantly more fre-
quent in elderly hypertensive patients, indicating that abnormal
iNOS-mediated NO formation may affect longevity in patients
with moderate to severe hypertension (Glenn et al., 1999). In addi-
tion, cardiac overexpression of iNOS in mice leads to increased
mortality, which is associated with gross ventricular dilation and
hypertrophy, and sudden cardiac death due to bradyarrhythmia
(Mungrue et al., 2002). Taken together, these data suggest that
altered patterns of NO generation/turnover contribute to greater
susceptibility to cardiovascular disorders in elderly, and that its
regulation may decrease the risk of aging-associated diseases.
NO GENERATION IN CARDIOVASCULAR AGING
eNOS-derived NO is a fundamental mediator of vascular home-
ostasis (Moncada and Higgs, 2006). NO mediates vasodilation,
inhibits leukocytes adhesion, and has antithrombotic and anti-
apoptotic effects. Several studies in human and animal models
have shown that endothelium-dependent vasodilatation, a marker
of endothelial function, progressively declines with age (Gerhard
et al., 1996; Taddei et al., 2001; Muller-Delp et al., 2002; Blackwell
et al., 2004; Sun et al., 2004; Delp et al., 2008; Rodriguez-Manas
et al., 2009). Age-associated infirmities such as arterial hyperten-
sion, atherosclerosis, heart failure, and neurodegenerative diseases
have endothelial dysfunction as a common vascular component.
Reduced NO bioavailability in aging is a consistent feature in
experimental and clinical studies. Vascular aging is accompanied
by reduced eNOS expression/activity or augmented breakdown
of NO by ROS. In addition, senescent endothelial cells pheno-
type shifts toward an inflammatory state, with up-regulation of
adhesion molecules, cytokines, and chemokines (Ungvari et al.,
2004). This phenotype favors platelet aggregation and inflamma-
tory cell adhesion, which may progress to thrombotic and ather-
osclerotic events. The expression of pro-inflammatory enzymes,
such as cyclooxygenase-2 (COX-2) and iNOS is induced by aging-
associated endothelial dysfunction (Ungvari et al., 2004). COX-2-
derived lipid mediators can contribute to enhanced reactivity to
vasoconstrictors (Briones et al., 2005; Novella et al., 2011). In addi-
tion, iNOS-derived high levels of NO can induce post-translational
modification of proteins or react with ROS to produce RNS, which
increases vasoconstrictor tonus in aged arteries.
The major molecular mechanisms of age-related endothelial
dysfunction involve at least three NO-associated events: NO con-
sumption by •O−2 overproduction, reduced vascular antioxidant
ability, and altered NOS enzymes expression/activity. Vascular
oxidative stress also interferes with the actions of endothelial cell-
derived NO on vascular smooth muscle cells. Treatment of old
animals with antioxidants or the exposure of arteries isolated
from old mice to antioxidants restores endothelium-dependent
dilation (Blackwell et al., 2004; Fleenor et al., 2011). The main
vascular sources of ROS have been identified in aging: detaching
mitochondria (Ungvari et al., 2010) and nicotinamide adenine
dinucleotide phosphate (NADPH)-oxidase (NOx; Hamilton et al.,
2001; Fleenor et al., 2011). As will be discussed, NOS can also act as
a •O−2 generator. Antioxidant enzymes such as superoxide dismu-
tase, glutathione, and catalase are also down-regulated or exhibit
decreased activity with aging (Sun et al., 2004; Lund et al., 2009;
Denniss et al., 2011; Fleenor et al., 2011). The final consequence
is an unbalanced ROS production and NO depletion in detriment
of the antioxidant capacity.
Identifying the changes that each NOS isoform undergoes in
vascular aging not only may help us to understand the natural
adaptations of the NO pathways in the cardiovascular system
with progressive aging, but may also provide novel targets for the
treatment of aging-associated CVD.
EFFECTS OF AGING ON VASCULAR NOS ISOFORMS
EFFECTS OF AGING ON eNOS
The role of aging on eNOS expression is controversial. Vascu-
lar eNOS expression with advancing aging has been shown to
be either unchanged (Sun et al., 2004; Rodriguez-Manas et al.,
2009; Yang et al., 2009), decreased (Challah et al., 1997; Yoon et al.,
2010), or increased (Cernadas et al., 1998; Matz et al., 2000; van
der Loo et al., 2000; Goettsch et al., 2001). Although data on
eNOS expression are contradictory, it is well accepted that the
activity of eNOS is reduced in aging (Cernadas et al., 1998; Chou
et al., 1998; Smith et al., 2006a,b; Yoon et al., 2010). Particularly,
eNOS activity is decreased by deficient availability of substrates or
cofactors, subcellular location, protein–protein interactions, and
post-translational modifications such as acylation, nitrosylation,
O-GlcNAcylation, and phosphorylation (Dudzinski and Michel,
2007; Villanueva and Giulivi, 2010).
Plasma membrane-associated eNOS represents an immediately
available agonist-sensitive pool of the enzyme (Dudzinski and
Michel,2007;Villanueva and Giulivi,2010). In old rats, the amount
of eNOS localized in the endothelial cell plasma membrane is
reduced (Smith et al., 2006b). In addition, senescent endothe-
lial cells in vitro display reduced NO synthesis accompanied by
increased eNOS linkage with caveolin-1 (Yoon et al., 2010), a pro-
tein whose interaction with eNOS keeps the enzyme inactivated in
a region of the plasma membrane named caveolae (Dudzinski and
Michel, 2007). eNOS activity is extended by protein–protein asso-
ciation with heat shock protein 90 (hsp90), a chaperone involved
in protein trafficking and folding (Dudzinski and Michel, 2007).
Hsp90 expression and binding to eNOS is reduced in old endothe-
lial cells (Smith et al., 2006b; Yoon et al., 2010). Together, these
may partially explain the decreased eNOS activity and the reduced
NO-dependent vascular relaxation in elderly, as summarized in
Figure 1.
In the presence of low intracellular Ca2+ levels, eNOS activity
is maintained by phosphoinositide-3-kinase (PI3K)/Akt-mediated
phosphorylation of serine 1176 (S1176) or 1177 (S1177), in rat and
human, respectively (Dudzinski and Michel, 2007). In contrast,
phosphorylation of eNOS at threonine 494 (T494) negatively reg-
ulates its activity (Dudzinski and Michel, 2007). Reduced eNOS
phosphorylation at S1176/S1177 and enhanced phosphorylation at
T494 have been reported in endothelial cells from aged rats (Smith
et al., 2006a) and senescent human endothelial cells in vitro (Yoon
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et al., 2010). Together, these data further support a role for reduced
eNOS-produced NO in aging-associated vascular dysfunction.
Glycosylation with O-linked-β-N -acetylglucosamine (O-
GlcnAc) is a post-translational modification of nuclear and cyto-
plasmic proteins. O-GlcNAc modification of eNOS seems to
reduce eNOS phosphorylation at Ser1177 and, consequently, eNOS
activity (Lima et al., 2009). The vascular content of O-GlcNAc-
modified proteins is augmented in the vasculature of old animals
(Fulop et al., 2008). Although the amount of vascular O-GlcNAc-
modified eNOS in old animals has not yet been determined, it is
possible that senescence-associated increased vascular O-GlcNAc
levels can also contribute to eNOS dysfunction in aging.
In addition to its reduced NO-releasing ability, eNOS seems to
play a deleterious role in aging. Accordingly, endothelium removal
reverses the increased vascular •O−2 production associated with
aging (van der Loo et al., 2000). Furthermore, aging-associated
vascular oxidative stress is partially reversed by pharmacologi-
cal NOS inhibition (Kim et al., 2009; Yang et al., 2009), which
suggests that eNOS contributes to •O−2 generation. As already
mentioned, uncoupled eNOS is a source of •O−2 in the vasculature.
In fact, the ratio of monomeric eNOS is increased in mesen-
teric arteries from aged rats, indicating that eNOS uncoupling
is associated with increased •O−2 production (Yang et al., 2009).
In aging, eNOS uncoupling has been associated with reduced BH4
availability (Delp et al., 2008; Yang et al., 2009) rather than defi-
ciency of l-arginine (Gates et al., 2007). Despite that, inhibition
of arginase, an enzyme that degrades l-arginine, restores eNOS
coupling in rat aortas (Kim et al., 2009). Moreover, addition of
sepiapterin, a BH4 precursor, ameliorates vascular relaxation in
conduit and resistance arteries from aged animals (Blackwell et al.,
2004; Delp et al., 2008) and reverses eNOS uncoupling (Yang et al.,
2009).
EFFECT OF AGING ON iNOS
iNOS expression is consistently reported in aged vessels, mainly in
the intima layer (Cernadas et al., 1998; Chou et al., 1998; Goettsch
et al., 2001; Csiszar et al., 2002; Rodriguez-Manas et al., 2009; Tian
et al., 2010). Pharmacological selective inhibition of iNOS pre-
vented age-related decrease of cardiac function (Yang et al., 2004)
and reversed impaired endothelium-dependent vasorelaxation in
old rats (Tian et al., 2010) and in elder subjects (Rodriguez-
Manas et al., 2009). These exciting data reveal a new patho-
logical mechanism involving iNOS in the abnormal constrictor
vascular tone associated with aging. This is also reinforced by a
recent report demonstrating iNOS up-regulation in microves-
sels of hypertensive subjects, and an impressive restoration of
endothelium-dependent vasodilation by a selective iNOS inhibitor
in hypertensive patients (Smith et al., 2011).
The mechanism of iNOS-induced vascular dysfunction in
aging is not completely elucidated. Aging-associated iNOS up-
regulation is accompanied by RNS peroxynitrite (ONOO−) pro-
duction (van der Loo et al., 2000), due to the reaction of NO
with •O−2 , which is facilitated in the pro-oxidant environment
of aged arteries. ONOO− is a potent and harmful molecule to
cellular lipids, genetic material, and proteins (Peluffo and Radi,
2007). Intense immnunostaining for nitrotyrosine, a marker of
protein nitration by ONOO− (Peluffo and Radi, 2007), is found
in aged vessels (Csiszar et al., 2002; Rodriguez-Manas et al.,
2009; Tian et al., 2010). Furthermore, a pharmacological scav-
enger of ONOO− reversed the reduced endothelium-dependent
dilation of arteries from old rats (van der Loo et al., 2000),
implicating ONOO− in aging-associated endothelial dysfunction
(Figure 1).
The amount of NO produced by iNOS is substantially greater
than that produced by the constitutive isoforms, and NO itself
may act as a cytotoxic agent and induce tissue damage (Hecker
et al., 1999; Moncada and Higgs, 2006). The reaction between NO
with cysteine residues of target proteins forming S-nitrosothiol
(SNO) is denominated S-nitrosylation, and it modifies protein
function (Moncada and Higgs, 2006). Arginase is a target pro-
tein for S-nitrosylation, and this post-translational modifica-
tion increases the enzyme activity. Increased S-nitrosylation of
arginase has been implicated in the decreased NO production
and reduced endothelium-dependent relaxation in aortas from
old rats (Santhanam et al., 2007). Interestingly, pharmacolog-
ical inhibition of iNOS abrogated arginase S-nitrosylation and
restored endothelium-dependent vasodilation (Santhanam et al.,
2007), indicating that increased arginase activity depends on iNOS
(Figure 1).
EFFECTS OF AGING ON nNOS
Although the regulatory roles of eNOS and iNOS in vascular aging
have been studied, just a small amount of information on the
contribution of nNOS to aging-associated vascular dysfunction is
available. In addition, there is limited knowledge on how nNOS
modulates vascular tone (Melikian et al., 2009).
Electrical stimulation of endothelium-denuded small arter-
ies causes α-adrenergic vasoconstriction, which is attenuated by
nNOS. However, this negative modulatory effect by nNOS is signif-
icantly impaired in old rats (Ferrer and Balfagon, 2001). Further-
more, old hypertensive rats exhibit just a minor increase of vaso-
constriction after pre-incubation with a selective nNOS inhibitor
(Ferrer et al., 2003). These findings suggest that nNOS-derived
NO in perivascular nitrergic innervation modulates microvascu-
lar tone by reducing α-adrenergic vasoconstriction and that its
absence may account for the abnormal vasoconstrictor tone in
aged arterioles (Ferrer and Balfagon, 2001; Ferrer et al., 2003). Of
importance, more studies on nNOS function in the vasculature of
aged animals as well as in aging-associated vascular dysfunction
are necessary and expected.
DRUGS THAT AFFECT NO GENERATION/TURNOVER: A
TREATMENT FOR AGING-ASSOCIATED VASCULAR
DYSFUNCTION IN HUMANS?
Due to its protective role on vascular homeostasis, adequate NO
synthesis and signaling represents an important goal in the treat-
ment of vascular dysfunction. Therefore it is important to under-
stand the cellular and molecular mechanisms that control the func-
tion and expression of NOS isoforms as well as the implications
this may have for aging-associated vascular dysfunction. Unfor-
tunately, as specific NOS isoforms pharmacological inhibitors are
still limited for experimental interventions or local administration
in humans, the effects of selective NOS activity inhibition and/or
stimulation remains unknown.
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RESTORING NO LEVELS
Due to their ability to restore reduced NO bioavailability, NO-
donors represent a therapeutic strategy to treat aging-associated
CVD. Although acute administration of the NO-donor sodium
nitroprusside improved cardiovascular performance at rest and
during exercise in healthy older volunteers (Chantler et al., 2011),
inorganic and organic nitrates (e.g., nitroglycerin) are a class
of compounds with limited long-term therapeutic use due to
the induction of tolerance. Experimentally, NO-releasing non-
steroidal anti-inflammatory drugs (NO-NSAID), which are pro-
drugs that contain a NO-donor moiety chemically attached to a
parent NSAID, have shown promising anti-inflammatory activity
and NO-releasing properties (Fiorucci et al., 2001). NO-releasing-
aspirin, but not aspirin, reduced vascular smooth muscle cell
proliferation in response to vascular injury in old rats (Napoli et al.,
2002), an effect that may be clinically relevant in the treatment of
aging-associated vascular remodeling.
An emerging alternative to directly increase NO levels is rep-
resented by nitrite anions. Different schedules of inorganic nitrite
supplementation as well as nitrite-rich diets have been shown to
induce vascular relaxation and to reduce blood pressure (Cosby
et al., 2003; Larsen et al., 2006; Webb et al., 2008; Kapil et al., 2010).
A traditional Japanese diet, for a 10-day-period, increased plasma
levels of nitrite and lowered blood pressure in healthy volunteers
(Sobko et al., 2010). These results suggest that the higher longevity
in the Japanese population compared to the occidental population
may be associated with high levels of nitrites on their diet. There is
a general agreement that inorganic and dietary nitrites can be ther-
apeutically used to treat CVD and possibly, cardiovascular aging.
However, uncertainties about the safety of nitrites limit clinical
interventions. To our knowledge, there is just one report showing
an association between high nitrite consumption and increased
regional brain perfusion in elderly subjects (Presley et al., 2011).
Since cerebral hypoperfusion precedes and contributes to the onset
of clinical dementia, this finding has clinical relevance.
STATINS
Inhibitors of cholesterol synthesis, the statins, represent a thera-
peutic alternative to treat vascular aging. In addition to improve-
ment in lipid profile, these drugs increase NO bioavailability by
many mechanisms that include: increased eNOS expression due to
increased eNOS mRNA stability and post-transcriptional modifi-
cations (Laufs and Liao, 1998; Laufs et al., 1998), eNOS recoupling
(Wenzel et al., 2008; Sabri et al., 2011), and reduced NO breakdown
by ROS (Figure 2) (Wagner et al., 2000; Wenzel et al., 2008). Addi-
tionally, atorvastatin up-regulates nNOS expression in endothelial
cells in vitro, and about a quarter of the total NO production in
aortic rings were attributed to atorvastatin-induced nNOS expres-
sion (Nakata et al., 2007). These pleiotropic effects of statins help
to justify the huge number of clinical trials addressing the benefits
of statin treatment in CVD (revised by Baigent et al., 2005).
Experimentally, statins reverse impaired endothelium-
dependent vasodilation in old rats and increase vascular lev-
els of eNOS (de Sotomayor et al., 2005). Conversely, impaired
endothelium-dependent vasodilatation was not modified by ator-
vastatin treatment in elderly subjects without associated morbidi-
ties (Weverling-Rijnsburger et al., 2004). Although this finding
seems to be disappointing, observational studies reported that
statin treatment lowered the ratio of fatal outcomes in elderly with
CVD (Foody et al., 2006; Gransbo et al., 2010). In the double-blind,
randomized, placebo-controlled multicenter study PROspective
Study of Pravastatin in the Elderly at Risk (PROSPER), pravas-
tatin was found to reduce death caused by coronary heart disease
and the risk for non-fatal myocardial infarction in the treated
elderly group (Shepherd et al., 2002), reinforcing the suggestion
that statins may prevent cardiovascular aging.
Transgenic mouse with endothelial-targeted overexpression of
guanosine triphosphate cyclohydrolase-1 (GTPCH-1), the rate-
limiting enzyme for de novo BH4 synthesis, does not exhibit
diabetes-associated vascular abnormalities (Alp et al., 2003).
Whereas streptozotocin (STZ) increases vascular oxidative stress
and impairs NO-mediated endothelium-dependent vasodilata-
tion in control mice, STZ-treated transgenic GTPCH-1 mice
exhibit less superoxide production and normal NO-mediated
vasodilatation (Alp et al., 2003). Similarly, treatment of hyper-
tensive rats with simvastatin restored GTPCH-1 activity and the
BH4/eNOS/NO pathway reversing the hypertension-associated
endothelial dysfunction (Zhang et al., 2012). In vitro, statins
rapidly increase BH4 bioavailability and up-regulate GTPCH-1,
leading to eNOS recoupling and NO generation in endothelial
cells (Hattori et al., 2003; Aoki et al., 2012; Zhang et al., 2012).
Of importance, patients with coronary artery disease treated with
atorvastatin showed very early improvement of flow-mediated
dilation in the brachial artery and restored BH4 levels in mam-
mary arteries compared with the placebo group (Antoniades et al.,
2011). Moreover, the incubation of human mammary arteries with
atorvastatin augmented GTPCH-1 expression (Antoniades et al.,
2011). Collectively, experimental findings indicate that statins pro-
duce beneficial vascular effects via actions in the GTPCH/BH4/NO
pathway and may be used for the treatment of vascular aging.
HORMONE THERAPIES: DEHYDROEPIANDROSTERONE (DHEA) AND
ESTROGEN
Therapy with hormones,mainly dehydroepiandrosterone (DHEA)
and estrogen, has been considered a “treatment for aging”
(Figure 2) (Lamberts et al., 1997). DHEA replacement ther-
apy improved endothelium-dependent dilation in normotensive
hypercholesterolemic men and post-menopause women (Kawano
et al., 2003; Williams et al., 2004). One potential explanation for
the above observations is based on experimental data on DHEA-
treated old rats. These animals showed increased aortic eNOS
expression and restored NO production, although the repercus-
sion on vascular function was not investigated (Wu et al., 2007).
Disappointingly, a set of clinical observations reported null effects
with DHEA supplementation in men with CVD (Traish et al.,
2011).
Despite of the controversy about the benefits of estrogen
replacement therapy in post-menopausal women, cardiovascu-
lar benefits of estrogen have been attributed to its modulatory
effects on NO generation by NOS isoforms (Xing et al., 2009).
Estrogen deficiency, induced by ovariectomy, further increased
aging-associated vasoconstriction and impaired NO signaling
(Stice et al., 2009; Novella et al., 2010). Estrogen replacement
also improved flow-induced vasodilation in coronary arterioles
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FIGURE 2 | Drugs that affect NO generation/turnover by
modulating NOS enzymes.The drugs that modulate NOS enzymes
and, consequently NO production, act by changing three important
aspects of NOS enzymes function: activity, expression and
transcription: (1) activity; estrogen induces eNOS phosphorylation at
(S1177) to increase enzyme activity; statins and folic acid may cause
eNOS recoupling to increase eNOS activity and NO production; (2)
expression; statins and DHEA increase eNOS expression and,
consequently, NO generation; (3) transcription; statins and resveratrol
act at the transcriptional level of eNOS increasing its mRNA stability. In
addition, resveratrol activates the promoter gene of eNOS increasing
its transcription. Whereas eNOS enzyme function can be altered in
three different ways, nNOS and iNOS function can be modulated at the
transcriptional level by some of these drugs. Statins may directly
induce nNOS transcription and increase nNOS protein levels. On the
other hand, resveratrol indirectly decreases iNOS transcription by
inhibiting NF-κB. DHEA, dehydroepiandrosterone; ROS, reactive oxygen
species; NF-κB, nuclear factor kappa B; mRNA, messenger RNA.
of aged and ovariectomized rats and restored eNOS phospho-
rylation (Ser1176), suggesting a positive regulation of estrogen
on eNOS activity in old females (LeBlanc et al., 2009). In addi-
tion, vascular dysfunction in aged female rats is associated with
both decreased levels of estrogen and an altered pattern of estro-
gen receptor-mediated NO-induced vascular relaxation (Novensa
et al., 2011). This provides a new insight for the refractoriness of
age-related vascular dysfunction to estrogen replacement therapy.
Beneficial and harmful effects of estrogen on the vasculature are
also associated to iNOS protein expression. Ovariectomized rats
exhibited greater vascular iNOS expression than intact animals and
estrogen replacement reduced iNOS expression in ovariectomized
rats (Tamura et al., 2000). Therefore, it is possible that vascular
dysfunction that accompanies estrogen withdrawal is related to
increased iNOS levels. However, estrogen replacement reversed
the vascular remodeling in injured arteries from ovariectomized
mice that do not express iNOS, suggesting that estrogen-associated
vascular protection is not only related to suppression of iNOS
expression/activity (Tolbert et al., 2001). Conversely, estrogen has
been shown to attenuate vasoconstriction by an estrogen receptor
beta-mediated increase in iNOS expression (Zhu et al., 2002). The
physiological significance of iNOS activation by estrogen on vas-
cular tonus remains uncertain, since the absence of either alpha
or beta estrogen receptors, which increases vascular iNOS, does
not affect vascular sensitivity to vasoconstrictors (Liang et al.,
2003). The protective effect associated with estrogen-induced
iNOS expression may be related to a reduction in thrombotic
events, since the gender-associated protection against experimen-
tally induced thrombosis is lost in female mice that do not express
iNOS (Upmacis et al., 2011). These data suggest that basal levels
of estrogen can actively produce NO via iNOS and inhibit throm-
bus formation in females. Although yet untested, it is unlikely
that estrogen replacement therapy elicits this effect, since a meta-
analysis of observational studies reported a statistically increase in
the risk for thromboembolic events among estrogen users (Nelson
et al., 2002).
With regard to nNOS, it was demonstrated that endothelium-
dependent relaxation of resistance arteries by estrogen is nNOS-
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dependent in female, whereas it is eNOS-dependent in males
(Lekontseva et al., 2011). Although the results of estrogen-induced
relaxation via nNOS are extremely encouraging, the physiological
significance of these findings has yet to be determined. Addi-
tionally, the effects of aging and estrogen replacement therapy
in this phenomenon are poorly understood and more studies
are needed. Finally, it must be considered that hormone replace-
ment therapy in women is usually prescribed as a combination
of estrogen and progestin (a synthetic analog of progesterone).
The estrogen/progestin association may cause differential vascu-
lar effects than those produced by estrogen alone (Qiao et al.,
2008).
RESVERATROL
Accumulating evidence support that resveratrol, a natural occur-
ring polyphenol derived from plants such as grapes, exerts anti-
aging effects. There are several genes and proteins known to
influence longevity, such as the mammalian target of rapamycin
(mTOR) – see a recent review and also a comment on topic (Cau
and Tostes, 2012; Ming et al., 2012) – and sirtuin families pathways,
which have been involved in the anti-aging properties of resver-
atrol (Pallàs et al., 2010). Whereas resveratrol extends lifespan in
yeast and nematode, the polyphenol has been shown to increase
survival rate in mice on a high-calorie diet. Resveratrol increased
insulin sensitivity and improved motor function in these animals
(Baur et al., 2006). In addition, resveratrol has been shown to
inhibit gene expression profiles associated with cardiac and skeletal
muscle aging, and prevent age-related cardiac dysfunction (Barger
et al., 2008). Of special interest, resveratrol prevents vascular cell
senescence by mechanisms that involve increased NO production
by eNOS via multifaceted signaling pathways (Schmitt et al., 2010).
Resveratrol not only restores eNOS activity, but it induces eNOS
transcription via direct activation of the eNOS gene promoter and
by increasing the stability of eNOS mRNA (Figure 2) (Wallerath
et al., 2002).
Due to these various effects, resveratrol treatment has been
experimentally tested and considered for a wide variety of CVD,
including hypertension, atherosclerosis, diabetes and metabolic
syndrome (Li et al., 2012). In general, there is a growing body of
evidence to support the benefits of red wine consumption (a rich
dietary source of resveratrol) to reduce CVD risk in obesity (Tim-
mers et al., 2011; Wong et al., 2011), diabetes (Kar et al., 2009;
Brasnyo et al., 2011), and coronary artery disease (Whelan et al.,
2004; Lekakis et al., 2005). A pilot study in older adults treated with
resveratrol reported a trend toward improved endothelial function
(Crandall et al., 2012); however, larger studies in elderly are still
awaited.
Although resveratrol-induced dilation of isolated small mesen-
teric arteries is similar in young and aged rats, treatment with
resveratrol reduces aging-associated vascular •O−2 production and
inflammation (Labinskyy et al., 2006). Resveratrol also reversed
eNOS uncoupling, reduced NO synthesis, and increased •O−2
production in senescent endothelial cells in vitro as well as in
aortas of aged rats (Rajapakse et al., 2011). Similarly, vascular
and cardiac eNOS recoupling was reported in resveratrol-treated
spontaneously hypertensive rats (Bhatt et al., 2011) and in a
mouse model of atherogenesis (Xia et al., 2010), respectively.
In addition, endothelium-dependent vasodilation was restored in
resveratrol-treated old rats (Rajapakse et al., 2011).
The anti-inflammatory properties of resveratrol are related
to its regulatory effects on the activity of transcription factors,
particularly NF-kappaB (NF-κB; Labinskyy et al., 2006). NF-
κB-induced expression of pro-inflammatory genes is involved
in aging-associated vascular dysfunction (Donato et al., 2009).
Therefore, inhibition of NF-κB by resveratrol may reverse the
increased iNOS expression in aged arterioles, and consequently
improve vascular function (Labinskyy et al., 2006). However, this
effect has not been experimentally demonstrated.
AGENTS TO REVERSE eNOS UNCOUPLING
Reversing eNOS uncoupling represents a therapeutic option to
treat CVD (Forstermann and Li, 2011; Zhang et al., 2011). While
most interventions are experimentally restricted, eNOS cofactor
BH4 potentially leads to eNOS recoupling in the human vascula-
ture (Forstermann and Li, 2011; Zhang et al., 2011). Infusion of
BH4 has been shown to recover eNOS bioactivity in hypercho-
lesterolemic patients, hypertensive subjects, and smokers (revised
by Forstermann and Li, 2011; Zhang et al., 2011). Importantly,
improved endothelium-dependent vasodilation associated to BH4
infusion was significantly more pronounced in elderly than in
young subjects (Higashi et al., 2006). A recent study showed
that an oral dose of BH4 increased carotid artery compliance
and brachial artery flow-mediated dilation in post-menopausal
women (Moreau et al., 2012). The authors also addressed whether
BH4 and estrogen co-administration would bring additional
improvement in vascular function, but no further effects were
observed (Moreau et al., 2012). It is important to highlight that
these studies were performed with acute doses of BH4 and,
although promising, BH4 supplementation potentially leads to
excessive and tissue unspecific NO production and toxicity (Moens
and Kass, 2006).
Interactions of 5-methyltetrahydrofolate (5-MTHF), the active
metabolite of folic acid, with eNOS protein have been described
(Moens et al., 2008). Likewise, 5-MTHF restores the bioavailabil-
ity of BH4 by increasing the binding affinity of BH4 to eNOS, by
chemically stabilizing BH4, and by enhancing the regeneration of
BH4 from its inactive form BH2 (Figure 2) (Moens et al., 2008).
5-MTHF reversed eNOS uncoupling and restored NO-mediated
vasodilation and reduced vascular superoxide, both ex vivo and
in vivo (Antoniades et al., 2006). Interestingly, this study was
performed in early elderly subjects (67.2± 0.97 years old) with
coronary artery disease (Antoniades et al., 2006). Similarly, the
treatment of hypertensive mice with folic acid prevented aneurism
formation and promotes eNOS recoupling (Gao et al., 2012).
At least two limitations on folic acid enrichment must be
pointed out. First, high levels of folic acid can mask the diag-
nosis of pernicious anemia (deficiency of vitamin B12) and allow
the neuropathy to progress undiagnosed. This could be particu-
larly limiting for the elderly, where substantial ratio of plasmatic
levels of non-metabolized folic acid was found after supplementa-
tion (Obeid et al., 2011). However, this can be easily corrected
by co-supplementation with vitamin B12 which further ame-
liorates coronary flow parameters (Kurt et al., 2010). Second,
the significance of folic acid supplementation to prevent major
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cardiovascular events was recently questioned in a systematic revi-
sion of clinical studies (Zhou et al., 2011), and whether this mech-
anism on eNOS recoupling occurs in old people treated with folic
acid and represents a rational therapeutic target remains unclear.
CONCLUSION AND PERSPECTIVES
The mechanisms by which NOS enzymes promote vascular dys-
function in aging are specific for each enzyme isoform. eNOS
expression and activity are decreased in aging, resulting in
reduced NO synthesis. Advancing aging is also accompanied by
eNOS uncoupling, which contributes to vascular oxidative stress.
iNOS expression is augmented in elderly, leading to reduced
endothelium-dependent vasodilation and increased damage via
formation of the reactive specie peroxynitrite. Possibly, an impair-
ment of perivascular nNOS-released NO increases vasoconstrictor
tone. These data suggest a differential regulation of the NOS family
isoforms in the process of vascular aging, which is associated with
reduced NO and increased •O−2 production, and to the vascular
dysfunction that lead to aging-related CVD.
Due to additional effects on the NOS pathway, e.g., restoration
of eNOS activity and decreased RNS formation, drugs clinically
used to treat hypercholesterolemia and post-menopause symp-
toms, such as statin and estrogen, respectively, have also been
considered for the treatment of cardiovascular aging. Dietary alter-
natives to treat vascular aging include nitrite-rich meals and folic
acid supplementation, although many questions on the safety
and effectiveness of long-term regimes were not elucidated so
far. Resveratrol is accepted as a key pharmacological agent for
prevention and treatment of aging, which interferes at multiple
molecular levels in aging-related vascular dysfunction. Although
it is clear that all the pharmacological agents reviewed herein
produce important and beneficial cardiovascular effects, it is nec-
essary to clinically determine whether these treatments extend
lifespan.
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